MeiraGTx

MeiraGTx is a vertically integrated, clinical-stage genetic medicine company developing therapies for rare and prevalent diseases. Its technical expertise covers genetic medicine, viral vector manufacturing, riboswitch gene regulation, metabolic therapy, and cell therapy, reflecting a deep-tech approach to therapeutic innovation.

The company's pipeline includes late-stage clinical programs for genetic therapies targeting eye diseases, salivary gland diseases, and neurological disorders. A key platform is its riboswitch gene regulation system, which enables controlled transgene expression for delivering metabolic peptides such as GLP-1 and cell therapies for conditions including tumors and autoimmune diseases.

MeiraGTx has over nine years of development experience, having developed more than 20 viral vectors. It operates GMP-licensed manufacturing facilities in the United States, United Kingdom, and Ireland, supporting its four late-stage clinical programs across ophthalmology, neurology, oncology, and other industry verticals.